Drug targets for Cancer: LIGHT

Drug Targets for Cancer: LIGHT and Cancer

LIGHT (TNFSF14) is an immunostimulatory cytokine that has been shown to augment the anti-cancer immune response and whose overexpression we identified as being associated with improved overall and recurrence free survival in patients with colorectal cancer liver metastases. A member of the Tumor Necrosis Factor Superfamily (TNFSF), it bears close homology with lymphotoxin a-β, lymphotoxin α, and Fas ligand. LIGHT is expressed predominantly on lymphocytes, and it principally interacts with two receptors – Lymphotoxin β receptor, located on other lymphocytes, and herpesvirus-entry-mediator (HVEM), which is located mainly on stromal cells. Forced LIGHT overexpression in tumors leads to increased levels of cytotoxic T lymphocytes (CTLs) in and around the tumor and can induce cancer regression. LIGHT may allow CTL's to overcome the antigenic barrier formed by host cell stroma around the tumor and to mount an anti-cancer response.

Drug Targets for Cancer: LIGHT related Products

Other vital drug targets for cancer like LIGHT:

Drug Targets for Cancer: LIGHT Related Reference

Qin JZ, Upadhyay V, Prabhakar B, Maker AV. Shedding LIGHT (TNFSF14) on the tumor microenvironment of colorectal cancer liver metastases. Journal of Translational Medicine. 2013;11:70.

Drug Targets for Cancer: LIGHT Related Information